報價延遲最少15分鐘:2025/01/21 19:06 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.69/-0.01
|
|
企業價值
146.47M
|
| 資產負債 |
|
每股賬面淨值
-0.16
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
58.45M
|
|
每股收益
1.25
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 19:06 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery. |